SURGICAL BIOLOGICS  ·  LAPAROSCOPIC & ROBOTIC

Adhesion Barrier. Dual-layer amniotic membrane

A chorion-free, dual-layer amniotic membrane allograft for open, laparoscopic, and robotic procedures — in partnership with Total Surgical. Deploys through a standard 10–12 mm trocar, handles simpler than MiMedx or Integra alternatives, and may reduce post-operative adhesions while facilitating healing.

Schedule a consultation → Surgical applications
da Vinci Xi surgical system with four articulated arms ready for laparoscopic adhesion-barrier deployment
The Problem

Adhesions — the hidden tax on every abdominal case.

Post-operative adhesions are the leading cause of chronic pelvic pain, secondary infertility, small bowel obstruction, and reoperation complications. MIS reduces the rate — but does not eliminate it.

Published incidence

55–93%

of intra-abdominal surgeries form post-operative adhesions across published pelvic and abdominal MIS literature. Every case is a candidate for a barrier conversation.

Downstream cost

Four clinical tolls

Chronic pelvic pain. Secondary infertility. Small bowel obstruction. Reoperation. The cost is carried by the patient and by the system — long after the OR lights come down.

Workflow reality

3–5 added minutes

At closure. No new instruments. No change to docking or port placement. No learning curve for scrub or circulator. A barrier program adopted now runs uninterrupted.

References: Diamond & Freeman 2001; Trew 2004; Brill et al. 2011. Published incidence ranges reflect pelvic and general MIS literature.

Mechanism of Action

Four mechanisms. One tissue.

Synthetic barriers are passive. Amniotic membrane is doing four things at once inside the 5–7 day adhesion-formation window.

01 · Physical

Physical barrier

Smooth epithelial surface separates healing peritoneum from adjacent structures during the critical 5–7 day adhesion-formation window.

02 · Biologic

Anti-inflammatory signaling

Native cytokines — TGF-β, IL-10, MMP inhibitors — actively modulate the fibrotic cascade instead of just blocking it.

03 · Regenerative

ECM scaffold

Collagen IV, V, VII and hyaluronic acid support healing toward normal tissue, not scar. Growth factors (EGF, VEGF, TGF-α, IGF-1) drive re-epithelialization.

04 · Bioresorbable

Fully resorbable

No foreign-body reaction. No second surgery. No lifelong implant. Contains no Class II antigens — immune-privileged, reducing the risk of patient reaction.

In-OR Workflow

Your team places the second sheet as comfortably as the first.

No new instruments. No change to docking or port placement. No learning curve for scrub or circulator.

Step 01

Select size

Pre-cut sheets sized for common applications — 4×4, 4×6, 4×8, 6×6 cm — or trim to field. Additional sizes available on request.

Step 02

Hydrate

Saline bath, 30–60 seconds, while finishing the procedure. No dry-field requirement — unlike Interceed.

Step 03

Deploy through trocar

Roll and pass through a standard 10–12 mm trocar. Thin, pliable, chorion-free membrane fits where bulkier allografts from MiMedx and Integra don’t.

Step 04

Position & secure

Standard laparoscopic graspers. Conforms to tissue and stays put. Suture-less placement. Added case time: 3–5 minutes at closure.

da Vinci articulating grasper instrument The Trocar Advantage

Thinner. Pliable. Fits where others don’t.

In laparoscopy specifically, every millimeter matters. A dual-layer, chorion-free membrane rolls smaller and passes through a standard port without fighting the sleeve — a handling reality that surgeons immediately feel versus the bulkier placental allograft category.

Handling vs. alternatives

Our dual-layer amnioticChorion-free — rolls thin, trocar-ready
MiMedx-category allograftsBulkier multi-layer — harder roll
Integra-category dermalMatrix scaffolds — not laparoscopy-shaped
Interceed (ORC)Requires a dry field — workflow-hostile in MIS
Seprafilm (HA-CMC)Brittle — fractures during trocar passage
PTFE / Gore-TexPermanent implant — not bioresorbable
SuturingNot required — membrane conforms and stays
StorageRoom temperature — no thaw, no freezer

Why this category wins in MIS

Only one product does regenerative work in addition to barrier function. Seprafilm and Interceed are passive. PTFE is permanent. Dermal-matrix products are shaped for open reconstruction, not robotic ports.

  • Barrier & activeAmniotic membrane is barrier + anti-inflammatory + ECM scaffold — the others are barrier only.
  • Fully resorbableUnlike PTFE, leaves nothing behind. No reoperation, no lifelong implant, no foreign-body reaction.
  • Wet-field readyNo dry-field requirement. Hydrates in saline while you finish the closure. Interceed can’t do this.
  • Trocar-shapedRolls and passes through a standard 10–12 mm port. Category alternatives are bulkier or open-only.
  • Suture-lessConforms to peritoneum and adjacent tissue. No fixation step, no added OR time beyond placement.
  • Room-temp storageAmbient storage in the OR core. No freezer, no thaw, no inventory headaches.

Workflow-neutral by design. No new instruments, no scrub re-training, no change to docking or port placement. The second sheet places as comfortably as the first.

Surgical Applications

Every abdominal & pelvic specialty. Every abdominal wall.

Allograft Tissue can be used in open incision, laparoscopy, and robotic surgery — including the da Vinci platform — wherever tissue separation and regenerative barrier function are indicated.

OBGYN

Urogynecology & gyn MIS

Hysterectomy. Oophorectomy. Myomectomy. Endometriosis excision. Highest adhesion rate in gyn — particularly for fertility-preserving myomectomy and deep endometriosis excision cases.

Colorectal

Colorectal surgery

Exploratory laparotomy with bowel resection. Lower anterior resection (LAR). Partial, hemi-, and total colectomy. Protects anastomoses and adjacent bowel during the adhesion-formation window.

Urology

Urologic reconstruction

Radical prostatectomy — open, laparoscopic, or robotic. Protects the neurovascular bundle and nearby structures during healing while minimizing post-operative fibrotic tethering.

Vascular

Vascular & access

FEMPOP bypass. AV fistula creation. Vascular anastomosis. Reduces inflammatory tethering at anastomosis sites and may support patency through active ECM signaling.

Indications and procedure-specific use are at the discretion of the operating surgeon. Additional specialties — including surgical oncology, hepatobiliary, and hernia repair — have reported clinical use of amniotic membrane allografts for adhesion prevention and soft-tissue coverage.

Product Specs

Resorbable & chorion-free amniotic membrane allograft.

Sourced from healthy, pre-screened, consenting mothers during planned, full-term Caesarean sections. Processed in the United States in accordance with AATB and FDA rules, regulations, and standards.

Specifications

ConfigurationChorion-free — two layers of amniotic membrane
ClassificationBi-modal allograft — barrier + regenerative
Growth factorsEGF · VEGF · TGF-α · IL-1rα · TGF-β1 · IGF-1
PropertiesAnti-inflammatory · anti-bacterial · re-epithelialization
ImmunogenicityNo Class II antigens — immune-privileged
ResorptionFully re-absorbable in vivo
PlacementSuture-less — conforms to tissue
StorageRoom temperature — no freezer, no thaw
ManufacturerTotal Surgical

Available sizes

Four standard configurations — pre-cut for common laparoscopic and open applications. Additional sizes available on request.

  • C204044 × 4 cm — port-site coverage, focal adhesion prevention
  • C204064 × 6 cm — myomectomy bed, adnexal protection
  • C204084 × 8 cm — sacrocolpopexy, endo excision, wider coverage
  • C206066 × 6 cm — hysterectomy cuff, colorectal anastomosis, prostatectomy bed

Benefits at a glance

  • May reduce adhesionsPhysical separation + active anti-fibrotic signaling during the 5–7 day formation window
  • May reduce scarringCollagen IV/V/VII and hyaluronic-acid scaffold support healing toward normal tissue
  • May decrease inflammationNative cytokines modulate the fibrotic cascade — not just a passive block
  • May facilitate healingGrowth factors and rich ECM drive re-epithelialization and regenerative repair
  • Low reaction riskNo Class II antigens — immune-privileged tissue, reducing patient reaction
  • Multiple pathwaysOpen incision, laparoscopy, and robotic — one product across your full case mix
Coding & Reimbursement

HCPCS C1762 — transitional pass-through.

Reimbursed under OPPS / ASC pass-through — in addition to the facility fee for the procedure. The surgeon bills their usual CPT. The patient pays nothing.

Coding & Coverage

HCPCSC1762 — "Connective tissue, human (includes fascia lata)"
PathwayOPPS / ASC transitional pass-through — active
Facility billingSeparate line — in addition to the procedure fee
Surgeon CPTNo change — bill your usual procedure code
Patient responsibilityZero out-of-pocket — not cash-pay, not out-of-network
Applicable POS22 (outpatient hospital) · 24 (ASC)

Three-party economics

Every stakeholder wins — which is why adoption sticks once it starts.

  • The facilityBills C1762 separately under OPPS/ASC pass-through — facility margin on every case
  • The surgeonZero coding change. Your CPT workflow stays identical — hysterectomy, myomectomy, prostatectomy, LAR
  • The patientNo financial conversation required. Not cash-pay. Not out-of-network. No surprise bill

Example commonly-paired CPTs

  • 58545 / 58546Laparoscopic myomectomy (± robotic)
  • 58571 / 58573Total laparoscopic hysterectomy (≤ 250 g / > 250 g)
  • 57425Laparoscopic sacrocolpopexy
  • 58662Laparoscopic excision of pelvic lesions (endometriosis)
  • 55866Laparoscopic radical prostatectomy
  • 44140 / 44204Colectomy · laparoscopic partial colectomy

Workflow-neutral, reimbursement-paid. The facility is made whole on every sheet, the surgeon bills their usual CPT, and the patient has zero out-of-pocket exposure. Our team walks your facility billing contact through the C1762 mechanics end-to-end before the first case.

C1762 pass-through status, payment, and coverage are determined by CMS and subject to change. Coverage and payment ultimately depend on payer policy and medical necessity. Our team confirms current pass-through status and works with your facility billing contact on a case-specific basis.

Common questions

What to know about our adhesion barrier.

Why is this easier to deploy than MiMedx or Integra alternatives? +
Our allograft is a chorion-free, dual-layer amniotic membrane — thinner and more pliable than the bulkier multi-layer placental allografts in the MiMedx category, and purpose-shaped for tissue separation rather than the dermal-matrix reconstruction Integra products are designed for. In laparoscopy specifically, the membrane rolls tighter and passes through a standard 10–12 mm trocar without fighting the sleeve. It also does not require a dry field (unlike Interceed), hydrates in 30–60 seconds of saline, and places without sutures.
How does amniotic membrane actually prevent adhesions? +
Four mechanisms work simultaneously during the critical 5–7 day adhesion-formation window: (1) a physical barrier separates healing peritoneum from adjacent structures; (2) native cytokines — TGF-β, IL-10, MMP inhibitors — actively modulate the fibrotic cascade; (3) a regenerative ECM scaffold of collagen IV/V/VII and hyaluronic acid supports healing toward normal tissue; (4) full bioresorption leaves nothing behind. Unlike passive synthetic barriers (Seprafilm, Interceed) or permanent implants (PTFE), this membrane is doing regenerative work in addition to barrier function.
Which procedures is it indicated for? +
Allograft Tissue can be used in open incision, laparoscopy, and/or robotic surgery procedures. Reported applications include: OBGYN — hysterectomy, oophorectomy, myomectomy, endometriosis excision, sacrocolpopexy. Colorectal — exploratory laparotomy with bowel resection, lower anterior resection, partial/hemi/total colectomy. Urology — radical prostatectomy (open, laparoscopic, or robotic). Vascular — FEMPOP bypass, AV fistula creation, vascular anastomosis. Use is at the operating surgeon’s discretion.
Does adopting it change our OR workflow? +
No. No new instruments. No change to docking or port placement. No learning curve for scrub or circulator. Four steps at closure: select size (or trim to field), hydrate 30–60 seconds in saline while finishing the procedure, roll and pass through a standard 10–12 mm trocar, position with standard laparoscopic graspers. Added case time: 3–5 minutes at closure. The second sheet places as comfortably as the first.
How does the C1762 pass-through actually work? +
C1762 is a CMS transitional pass-through HCPCS covering "connective tissue, human (includes fascia lata)." Under OPPS / ASC, the facility bills C1762 on a separate line in addition to the facility fee for the procedure. The surgeon bills their usual CPT — no coding workflow change. The patient has zero out-of-pocket: not cash-pay, not out-of-network. Our team walks your facility billing contact through C1762 mechanics end-to-end before the first case. Pass-through status is set by CMS and subject to change; we confirm current status on a case-specific basis.
Is the tissue safe? Where does it come from? +
Our amniotic membrane is sourced in the United States from healthy, pre-screened, consenting mothers during planned, full-term Caesarean sections. Donors undergo behavioral risk assessment, physical assessment, and communicable-disease testing. Processing is performed in compliance with American Association of Tissue Banks (AATB) and U.S. FDA rules, regulations, and standards. The tissue is chorion-free, contains no Class II antigens, and is considered immune-privileged — reducing the risk of patient reaction.
Why partner with Albacete MedDev for this program? +
With Albacete MedDev, the adhesion barrier arrives as a program — not a product drop-off. Our team provides billing-team walkthroughs on C1762 mechanics, OR in-services on handling and trocar deployment, and documentation support for your compliance and audit workflow. Across every one of our biologics and device programs, you gain access to our full compliance infrastructure, portal-integrated tracking, and in-house medical-legal guidance — so the clinical adoption stays clean from first case to year five.
Ready when you are

Add regenerative adhesion prevention to your OR.

A 30-minute consultation to walk through billing mechanics, OR in-service scheduling, and a low-friction pilot pathway that fits your case mix.

Schedule a consultation → Explore the portfolio